Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 8/20 | 0.47 |
| ▸ | RORC | P51449 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12678917 | 0.90 | ERN1 (0.38) | ERN1RORCCYP3A4ALOX5APFFAR4 | |
| SCHEMBL1542893 | 0.87 | ERN1 (0.42) | ERN1CYP3A4ALOX5APFFAR4FEN1 | |
| SCHEMBL1542307 | 0.87 | ERN1 (0.37) | ERN1RORCCYP3A4ALOX5APFFAR4 | |
| SCHEMBL2128477 | 0.87 | ERN1 (0.44) | ERN1CYP3A4ALOX5APMGAMGAA | |
| SCHEMBL12678912 | 0.85 | CYP3A4 (0.36) | ERN1RORCCYP3A4FFAR4FEN1 | |
| SCHEMBL12678826 | 0.85 | TLR8 (0.41) | ERN1RORCALOX5APMGAMGAA | |
| SCHEMBL13071658 | 0.84 | ERN1 (0.38) | ERN1CYP3A4FFAR4 | |
| SCHEMBL1542393 | 0.84 | ALOX5AP (0.40) | RORCALOX5APMGAMGAASI | |
| SCHEMBL12678910 | 0.84 | ERN1 (0.34) | ERN1RORCCYP3A4ALOX5APMGAM | |
| SCHEMBL12678914 | 0.84 | TDP1 (0.38) | ERN1RORCCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2432554-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010133528-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | CHIN ELBERT | 2010-11-25 | — | — | US | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297073-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | ERN1 147/4885RORC 752/4885CYP3A4 302/4885 |
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | ERN1 140/4885RORC 791/4885CYP3A4 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.